Literature DB >> 1955718

Immunoglobulin prophylaxis against milkborne transmission of human T cell leukemia virus type I in rabbits.

T Sawada1, Y Iwahara, K Ishii, H Taguchi, H Hoshino, I Miyoshi.   

Abstract

Prophylactic effect of human T cell leukemia virus type I (HTLV-I) immune globulin (HTLVIG) against milkborne transmission of HTLV-I was investigated in a rabbit model. Four litters (A-D: 7, 5, 7, and 7 offspring, respectively) born to an HTLV-I-infected rabbit were used. Litters A and D were allowed to grow normally as controls, while litters B and C were given weekly intraperitoneal inoculation of HTLVIG four times until weaning at 4.5 weeks of age. Only 1 (8.3%) of the 12 HTLVIG-inoculated rabbits, compared with 6 (42.9%) of the 14 control rabbits, seroconverted for HTLV-I. Gene amplification detected the presence of HTLV-I proviral sequences in all of the seroconverted but in none of the seronegative rabbits. These results suggest that passive immunization is effective in preventing dam-to-offspring transmission of HTLV-I.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1955718     DOI: 10.1093/infdis/164.6.1193

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

1.  Mouse models of human T lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma.

Authors:  B Zimmerman; S Niewiesk; M D Lairmore
Journal:  Vet Pathol       Date:  2010-05-04       Impact factor: 2.221

Review 2.  Animal models for human T-lymphotropic virus type 1 (HTLV-1) infection and transformation.

Authors:  Michael D Lairmore; Lee Silverman; Lee Ratner
Journal:  Oncogene       Date:  2005-09-05       Impact factor: 9.867

3.  Amino acid changes at positions 173 and 187 in the human T-cell leukemia virus type 1 surface glycoprotein induce specific neutralizing antibodies.

Authors:  S Blanchard; T Astier-Gin; B Tallet; D Moynet; D Londos-Gagliardi; B Guillemain
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

Review 4.  Clinical and Public Health Implications of Human T-Lymphotropic Virus Type 1 Infection.

Authors:  Nicolas Legrand; Skye McGregor; Rowena Bull; Sahar Bajis; Braulio Mark Valencia; Amrita Ronnachit; Lloyd Einsiedel; Antoine Gessain; John Kaldor; Marianne Martinello
Journal:  Clin Microbiol Rev       Date:  2022-02-23       Impact factor: 50.129

5.  Association between maternal antibodies to the external envelope glycoprotein and vertical transmission of human T-lymphotropic virus type I. Maternal anti-env antibodies correlate with protection in non-breast-fed children.

Authors:  S Hino; S Katamine; T Miyamoto; H Doi; Y Tsuji; T Yamabe; J E Kaplan; D L Rudolph; R B Lal
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

6.  Human T Lymphotropic Virus Type 1 (HTLV-1): Molecular Biology and Oncogenesis.

Authors:  Priya Kannian; Patrick L Green
Journal:  Viruses       Date:  2010-09-24       Impact factor: 5.818

Review 7.  Molecular determinants of human T-lymphotropic virus type 1 transmission and spread.

Authors:  Michael D Lairmore; Rajaneesh Anupam; Nadine Bowden; Robyn Haines; Rashade A H Haynes; Lee Ratner; Patrick L Green
Journal:  Viruses       Date:  2011-07-12       Impact factor: 5.048

8.  Cellular Factors Involved in HTLV-1 Entry and Pathogenicit.

Authors:  Hiroo Hoshino
Journal:  Front Microbiol       Date:  2012-06-21       Impact factor: 5.640

Review 9.  Animal Models Utilized in HTLV-1 Research.

Authors:  Amanda R Panfil; Jacob J Al-Saleem; Patrick L Green
Journal:  Virology (Auckl)       Date:  2013-11-18

10.  The neutralizing function of the anti-HTLV-1 antibody is essential in preventing in vivo transmission of HTLV-1 to human T cells in NOD-SCID/γcnull (NOG) mice.

Authors:  Mineki Saito; Reiko Tanaka; Hideki Fujii; Akira Kodama; Yoshiaki Takahashi; Toshio Matsuzaki; Hiroshi Takashima; Yuetsu Tanaka
Journal:  Retrovirology       Date:  2014-08-28       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.